Is there Evidence to Support the use of Enteric Coated (EC) Aspirin to Reduce Gastrointestinal Side Effects in Cardiovascular Patients?

· Guy's and St Thomas' NHS Foundation Trust

The enteric coated (EC) formulation was developed and marketed in an effort to reduce GI adverse effects associated with aspirin. This Q&A reviews the evidence on the use of EC aspirin to prevent GI damage, and the effect of the enteric coating on anti-platelet effect of aspirin.

AspirinCardiovascular system disordersGastrointestinal disordersQ&A

Attachments